- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.08. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 12 | SEC Filings | ||
| 04.08. | JIN MEDICAL INTERNATIONAL LTD. Reports First Half of Fiscal Year 2026 Financial Results | 192 | PR Newswire | CHANGZHOU, China, Aug. 4, 2026 /PRNewswire/ -- JIN MEDICAL INTERNATIONAL LTD. (Nasdaq: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated... ► Artikel lesen | |
| 15.07. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| JIN MEDICAL INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 04.06. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.04. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.04. | Jin Medical International Ltd. Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement | 256 | PR Newswire | CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated... ► Artikel lesen | |
| 17.03. | Jin Medical International Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.03. | Jin Medical announces 1-for-20 reverse stock split; shares down | 2 | Seeking Alpha | ||
| 12.03. | Jin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative | 534 | PR Newswire | CHANGZHOU, China, March 11, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CERENOME | 2,630 | +1,74 % | Cerenome, Inc.: Cerenome Reports Second Quarter 2026 Financial Results and Business Update | HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics... ► Artikel lesen | |
| HEALWELL AI | 0,467 | -0,43 % | HEALWELL AI: HEALWELL AI's DARWEN AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation | Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN AI as a globally recognized... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,220 | -2,63 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| CO-DIAGNOSTICS | 1,080 | -1,82 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| AMBU | 10,130 | +0,10 % | Ambu Q1 2025/26 slides: endoscopy growth offsets FX headwinds | ||
| LIFEWARD | 7,300 | +0,69 % | Lifeward Ltd.: Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth | Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support continued commercial... ► Artikel lesen | |
| IMUNON | 1,430 | +4,38 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen | |
| NOVACYT | 0,514 | +1,18 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.03.2026 | Das Instrument 00W AU000000ASP3 ASPERMONT LTD EQUITY wird cum Kapitalmassnahme gehandelt am 03.03.2026 und ex Kapitalmassnahme am 04.03.2026 The instrument 00W AU000000ASP3 ASPERMONT LTD EQUITY is traded... ► Artikel lesen | |
| INSPIREMD | 0,765 | +1,32 % | InspireMD Targets $9 Million Of Annual Cost Savings As CGuard TCAR Study Reports 100% Acute Device Success | ||
| MYOMO | 1,584 | -0,88 % | Myomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M | ||
| GT BIOPHARMA | 0,287 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Reports Second Quarter 2026 Financial Results | Phase 1 trial evaluating GTB-3650 TriKE- remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE- in multiple solid tumor types known to express B7-H3... ► Artikel lesen | |
| AETHLON MEDICAL | 2,800 | +0,72 % | Aethlon Medical, Inc.: Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier Program |
Conference Call Today at 4:30 p.m. ET
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical... ► Artikel lesen | |
| INOGEN | 4,880 | 0,00 % | Inogen (INGN) Cuts Guidance Even As Profitability Climbs | ||
| INTELLIGENT BIO SOLUTIONS | 2,760 | +3,37 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth | Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year... ► Artikel lesen |
Das Unternehmen JIN MEDICAL INTERNATIONAL LTD kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,27 % bei einem Aktienkurs von 3,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIN MEDICAL INTERNATIONAL LTD finden Sie auf Wallstreet Online.